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The bioterrorism-associated human anthrax epidemic in the fall of 2001 highlighted the need for a sensi-
tive, reproducible, and specific laboratory test for the confirmatory diagnosis of human anthrax. The Cen-
ters for Disease Control and Prevention developed, optimized, and rapidly qualified an enzyme-linked
immunosorbent assay (ELISA) for immunoglobulin G (IgG) antibodies to Bacillus anthracis protective anti-
gen (PA) in human serum. The qualified ELISA had a minimum detection limit of 0.06 µg/mL, a reliable
lower limit of detection of 0.09 µg/mL, and a lower limit of quantification in undiluted serum specimens of
3.0 µg/mL anti-PA IgG. The diagnostic sensitivity of the assay was 97.8%, and the diagnostic specificity
was 97.6%. A competitive inhibition anti-PA IgG ELISA was also developed to enhance diagnostic speci-
ficity to 100%. The anti-PA ELISAs proved valuable for the confirmation of cases of cutaneous and inhala-
tional anthrax and evaluation of patients in whom the diagnosis of anthrax was being considered.
aturally occurring anthrax is a zoonotic disease of herbi-
vores, with low-level sporadic infection of humans.
Since 1950, human anthrax in the United States was confined
to those occupationally at risk, with only 235 confirmed cases,
mostly cutaneous, reported from 1955 to 2002 (1–3). The
occurrence of human anthrax in the country and the public per-
ception of the disease changed dramatically in the fall of 2001,
with the first successful bioterrorist anthrax attack on the U.S.
civilian population. This event necessitated the simultaneous
development and application of qualified laboratory assays—
including serologic assays—to evaluate patients suspected of
having anthrax. 
The major obstacle to serologic analysis of human anthrax
has been the lack of assay standardization. Variations in anti-
gen preparation and purity, assay methods, and endpoint deter-
mination between laboratories and the absence of a suitable
standard reference serum compound this problem. The Centers
for Disease Control and Prevention (CDC) had, before the
attacks, instituted the development of anthrax serologic
assays—particularly enzyme-linked immunosorbent assays
(ELISAs)—for use in anthrax vaccine studies in humans and
to provide a standard human reference serum. In response to
the anthrax emergency of 2001, we report the accelerated
development and qualification of a quantitative ELISA for
detection of anti-protective antigen (PA) specific immunoglob-
ulin (Ig) G in human serum and the development of a competi-
tive inhibition assay to enhance diagnostic specificity. The
assays were applied to diagnosis of cutaneous and inhalational
anthrax to evaluate serologic responses in persons considered
at risk from anthrax spore exposure and enhance anthrax sero-
logic tests with standardized techniques for distribution to
public health and clinical laboratories. 
Methods
Antigen Preparation
Recombinant anthrax toxin protective antigen (rPA) with
an amino acid sequence concurring with that from the Bacillus
anthracis V770-NP1-R anthrax vaccine strain was obtained
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from  the National Institute of Craniofacial and Dental
Research, National Institutes of Health, Bethesda, MD. Anti-
gen was stored frozen at –80°C in small aliquots (10–100 µL,
4.75 mg/mL) in 5 mM Hepes, pH 7.3. Antigen was expressed
from the attenuated asporogenous host B. anthracis BH445
and purified to homogeneity as described (4). 
Human Serum for Determination of 
Diagnostic Specificity and Sensitivity
To determine the background level of anti-PA ELISA reac-
tivity in a cross-section of the U.S. population, a panel of 238
control sera from healthy adult persons was assembled from
the CDC Occupation Health Service and the National Health
and Nutrition Examination Survey (NHANES, CDC) serum
collections. Donors were selected on the basis of having no
known exposure to B. anthracis or anthrax and no known his-
tory of anthrax vaccination. In addition, a panel of 277 sera
was assembled from persons with clinically confirmed non-
anthrax-related illnesses (acute hepatitis A, acute hepatitis B,
influenza A and B, brucellosis, staphylococcal toxic-shock
syndrome, group A streptococcal infections, legionellosis,
Chlamydia pneumoniae infection, and Mycoplasma pneumo-
niae infection) and from children and adults who had received
non-anthrax-related vaccines (trivalent influenza, hepatitis B,
tetanus toxoid, and botulinum toxoid). To determine assay sen-
sitivity, an additional panel of 68 sera from persons who had
received anthrax vaccine adsorbed (AVA) and 19 control sera
from nonvaccinees was obtained. All sera were tested in dupli-
cate without heat inactivation.
Human Standard Serum Preparation
The anti-AVA standard human reference serum, AVR414,
was prepared by plasmapheresis of healthy adult CDC volun-
teers who had received at least four subcutaneous injections of
Anthrax Vaccine Adsorbed (AVA, BioPort Corp., Lansing, MI)
with the licensed regimen (0, 2, and 4 weeks; 6, 12, and 18
months; and yearly boosters). Plasmapheresis and serum con-
version were done at the Emory Transfusion Medicine Pro-
gram, Emory University School of Medicine (Atlanta, GA)
and the Scientific Resource Program at CDC, respectively.
Plasmapheresis was done by the TPE DUAL- NEEDLE proce-
dure with the COBE Spectra Apheresis System (Gambro BCT,
Inc., Blood Component Technology, Lakewood, CO) and fol-
lowing the manufacturer’s procedure manual (Manual
#701900–000 1999/1). Each plasma unit was clotted with ster-
ile glass microbeads (B. Braun Instruments, Burlingame, CA)
and suspended in 1.5 M CaCl2–2.0 M ε -amino-caproic acid.
All units were allowed to clot overnight at room temperature
and were then centrifuged at 2,200 x g at 4°C for 15 min. The
serum from each unit was stored in a 500-mL sterile plastic
container. The level of residual anticoagulants was not mea-
sured.  The total IgG concentration of the serum pool was
determined by radial immunodiffusion and nephelometry, with
the U.S. National Reference Preparation for Specific Human
Serum Proteins (CDC) as a standard (5). Anti-PA specific IgG
mass value assignment to the standard serum was done by dif-
ferential adsorption, homologous enzyme-linked immunoas-
say (EIA), and heterologous ELISA (Semenova VA, et al.,
manuscript in preparation), with U.S. Food and Drug Admin-
istration (FDA) 1983 Haemophilus influenzae type b (Hib) ref-
erence serum (6). 
ELISA Procedure
Polyoxyethylene sorbitol monolaurate (Tween 20) was
purchased from BioRad Laboratories (Hercules, CA). Skim
milk powder was obtained from Difco/Becton Dickinson
(Atlanta, GA). Horseradish peroxidase (HRPO)–conjugated
mouse anti-human IgG (affinity purified, γ -chain specific
monoclonal clone HP6043) was obtained from Hybridoma
Reagent Laboratories (Baldwin, MD). Peroxidase substrate
2,2´-azino-di(3-ethyl-benzthiazoline-6-sulfonate) (ABTS),
hydrogen peroxide (H2O2), and peroxidase stop solution were
obtained from Kirkegaard & Perry Laboratories (KPL, Gaith-
ersburg, MD). All other laboratory reagents were obtained
from Sigma Chemical Co. (St. Louis, MO) unless otherwise
specified. Sterile, Type I endotoxin-free water was used for all
ELISA procedures.
Immulon II-HB flat-bottom 96-well microtiter plates
(Thermo Labsystems, Franklin, MA), were coated for 16 hrs at
+4°C with 100 µL/well of rPA at a concentration of 2.0 µg/mL
in 0.01 M phosphate-buffered saline (PBS), pH 7.4  (Life
Technologies, Gaithersburg, MD). Plates were stored at +4°C
without blocking and used within 7 days of preparation. Anti-
gen-coated plates were then washed three times (ELX405
microplate washer, BioTek Instruments Inc., Winooski, VT)
with PBS containing 0.1% Tween 20 and blotted dry by inver-
sion on clean paper towels. Control and serum antibodies were
tested without a separate blocking step. Serum standards and
sera for testing were prepared at the appropriate dilutions in
PBS containing 5% skim milk and 0.5% Tween 20, pH 7.4.
The human standard reference serum and test sera were seri-
ally diluted twofold in the plate in the same buffer solution.
The minimum dilution of test serum was 1/50. Three positive
control sera from three separate donors and one negative con-
trol serum were each used at single dilution factors selected to
give a range of optical density (OD) values across the standard
reference curve. The final volume in all wells was 100 µL.
Test and standard sera were incubated in a humidified
chamber (covered tray) for 60 min at 37°C, and the plates were
then washed three times with PBS containing 0.1% Tween 20.
Bound anti-PA IgG was then detected by using HRPO-conju-
gated mouse anti-human IgG Fc PAN monoclonal HP6043
diluted in PBS containing 5% skim milk and 0.5% Tween 20
(100 µL/well), and plates were incubated in a humidified
chamber (covered tray) for 60 min at 37°C. Plates were again
washed three times with PBS containing 0.1% Tween 20, and
bound conjugate was detected colorimetrically by using
ABTS/H2O2 substrate (100 µL/well). Color development was
over 30 min (±5 min) and was stopped by addition of 100 µL
of Peroxidase Stop Solution (KPL) to all wells of the testEmerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1105
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plates. OD values were read within 30 min of addition of the
stop solution with a MRX Revelation microtiter plate reader
(Thermo Labsystems, Franklin, MA) at a wavelength of 410
nm with a 610-nm reference filter. Data were analyzed by
using a four-parameter (4-PL) logistic-log curve fitting model
with ELISA for Windows software (7). A calibration factor for
the standard reference serum was used to determine the con-
centration of anti-PA IgG in micrograms per milliliter of serum
(µg/mL). 
Competitive Inhibition ELISA
To enhance specificity, a supplementary rPA competitive
inhibition ELISA (CI-ELISA) was developed based on the
qualified anti-PA IgG ELISA. The CI-ELISA was a direct
extension of the standard ELISA procedure with the following
modifications. The anti-PA antibody concentrations of the test
sera were first determined by using the standard ELISA. Only
sera with a minimum reactivity level of 10 µg/mL anti-PA
antibody were suitable for evaluation in the CI-ELISA. The
10-µg/mL threshold was determined empirically as the mini-
mum level for which a reduction in ELISA reactivity could be
assigned with statistical significance. A concentration of 50 µg
rPA/500 µL diluted sample was chosen as the absorbing con-
centration after a preliminary study with ranges between 0 and
200 µg/mL (8). Test sera were then diluted to a concentration
calculated to provide an OD value of approximately 1.0, based
on their reactivity in the standard anti-PA ELISA. A 1-mL vol-
ume of each diluted serum was prepared and divided into two
aliquots of equal volume. To one of these aliquots, rPA was
added to a final concentration of 100 µg/mL. Both tubes were
capped tightly and mixed by inversion for 16–18 hrs at +4°C.
After this incubation, the tubes were centrifuged at 4°C for 10
min at 8,000 x g to remove precipitated materials. Test sera
were incubated in the presence and absence of an excess of
rPA in solution before analysis in the standard ELISA. 
The supernatants were used without further dilution in the
standard ELISA described above. Based on defined sera from
anthrax vaccine recipients and confirmed clinical cases, a
>85% suppression of reactivity in the competitive ELISA was
identified as the threshold to discriminate between true posi-
tives and false positives.
Accuracy, Precision, Limits of Quantification, 
and Goodness of Fit
Accuracy describes the exactness of the assay to measure a
known, true value of anti-PA IgG and to measure it repeatedly.
In this study, accuracy was determined by repeated analysis of
a positive control human anti-AVA antiserum for which differ-
ential absorption and heterologous ELISA had determined the
anti-PA IgG concentration. Accuracy is expressed as the per-
cent error between the assay-determined value and the
assigned value for that serum. A percent error of <20% is an
acceptable level of accuracy for an enzyme immunoassay (9).
Precision, a measure of the degree of repeatability of an assay
under normal operating conditions, is expressed as the coeffi-
cient of variation of the concentrations calculated for the stan-
dard reference curve dilutions within a single assay plate
(intraassay precision) and between different assay plates
(interassay precision) determined over time and controlling for
different operators. Acceptable levels of intraassay and inter-
assay precision are 10% and 20%, respectively (9), and these
can be used to define the range of the assay and the upper and
lower limits of quantification. The range of the assay is the
interval between the upper and lower levels of antibody (inclu-
sive) that have been demonstrated to be determined with these
levels of precision and accuracy. 
The “goodness of fit” of the assay is, for comparative pur-
poses, an indication of how closely the data points of the refer-
ence serum standard curve fit the 4-PL model. Goodness of fit
is expressed as the regression coefficient (R2) of the standard
curve. An R2 value that approaches unity is indicative of a
good fit for the data to the curve (9).
Limits of Detection of the Anti-PA IgG ELISA
The 4-PL function was used to model the characteristic
curve for the standards data. These data exhibit a sigmoidal
shape when plotted on an OD-log10 dilution scale. The 4-PL
function fits these data with a high degree of accuracy and
extends the range of the assay, thus providing a more precise
measurement of antibody concentration for patient sera (10).
The lowest concentration of analyte (anti-PA IgG) that can be
detected with a specific degree of probability in a diluted
serum sample is defined as the minimum detectable concentra-
tion (MDC). The lowest concentration of analyte that has a
high probability of producing a response significantly greater
than the response at zero concentration of analyte is defined as
the reliable detection limit (RDL). The MDC and RDL of the
anti-PA IgG ELISA were derived from a 4-PL fit applied to the
AVR414 standard reference serum (9). The MDC is the con-
centration of anti-PA antibody corresponding to the interpo-
lated intersection of the lower asymptote of the upper 95%
confidence interval (95% CI) with the 4-PL fit of the standards
data. The RDL is the concentration of anti-PA antibody corre-
sponding to the interpolated intersection of the upper 95% CI
asymptote with the lower-95% CI of the standards data. The
MDC and RDL are thus both derived from the 95% CIs of the
standard curve. They are distinct and statistically robust mea-
surements of the lower limits of detection of the assay; the
RDL is the more conservative of the two. An illustration of the
relationship of MDC and RDL to the standard curve is shown
(Figure). 
The reactivity threshold (Figure) is used to categorize a
serum as reactive or nonreactive and to determine the
diagnostic sensitivity (DSN) and diagnostic specificity (DSP)
of the assay. The reactivity threshold of this assay was deter-
mined from the frequency distribution (11) of log10-trans-
formed OD values from a panel of sera from humans with non-
anthrax-related clinical infections (554 observations) and a
panel of control human sera (476 observations). The reactivity
threshold was determined as the upper 95% CI of the frequencyBIOTERRORISM-RELATED ANTHRAX
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distribution from log10-transformed OD values of control
human sera tested at 1/50 dilution. This OD value was con-
verted to an anti-PA IgG concentration by using the standard
curve calibration factor. Where this calculated value is below
the MDC of the assay, the MDC becomes the default reactivity
threshold. Ideally, the MDC, RDL, and reactivity threshold will
all fall within the limits of quantification as defined above.
ELISA Diagnostic Sensitivity and Specificity 
The DSP and DSN of the anti-PA IgG ELISA were deter-
mined. The quantitative test results were categorized into reac-
tive or nonreactive by application of the reactivity threshold.
The DSP of the assay was calculated as [TN/(TN+FP)], where
TN = true negatives and FP = false positives. The DSN of the
assay was calculated as [TP/(TP+FN)], where TP = true posi-
tives and FN = false negatives. Initially, serum specimens from
clinical anthrax cases were insufficient to be useful in deter-
mining the DSN of the anti-PA IgG ELISA. Thus, the DSN
was calculated by using sera from a cohort of anthrax vaccine
recipients who had received a minimum of four subcutaneous
injections of AVA. The DSN of the assay was reevaluated at
the end of the anthrax emergency, when a greater number of
specimens from clinical cases had accumulated.
Human Sera from Patients with Confirmed 
or Suspected Anthrax or Exposure to B. anthracis Spores
The qualified anti-PA ELISA was applied to sera from per-
sons with confirmed or suspected anthrax cases and from per-
sons exposed to B. anthracis spores. Blood was collected in
serum separation tubes and allowed to clot; the serum was then
separated from clotted cells by low-speed centrifugation.
Serum was shipped to CDC with a unique identification num-
ber. All clinical serum samples were blinded to the laboratory
team and tested in duplicate. All ELISA-reactive sera were
tested a minimum of twice. The CI-ELISA was applied to sin-
gle serum specimens with a reactivity of >10 µg/mL and when
persons’ paired sera indicated reactivity in the absence of
changing anti-PA antibody concentrations over time. A >4-
fold rise over the calculated value for the acute serum or the
assay reactivity threshold was used to define seroconversion. 
Anti-PA IgG concentrations in test sera were calculated by
interpolation to the standard reference calibration curve by
using the ELISA for Windows Software Version 1.0 (7); anti-
PA IgG concentrations were expressed in micrograms per mil-
liliter of the original serum sample. For results to be report-
able, the assay was required to meet a set of quality control
acceptance criteria. For an acceptable level of precision, the
mean anti-PA IgG concentrations for three separate quality
control sera were required to calculate within 3 standard devia-
tions (SDs) of their assigned mean concentrations; at least two
of the mean anti-PA IgG concentrations for these sera were
required to be within 2 SDs of their respective assigned mean
values. Assay plates were also evaluated for parallelism
between the standard curve and the test samples (12).
Results
Performance Characteristics of the Anti-PA IgG ELISA
Feasibility, standardization, and performance of an ELISA
to detect IgG antibodies against the PA of B. anthracis were
completed during the anthrax epidemic of fall 2001. A human
serum pool (AVR203) for which the anti-PA IgG concentration
had been determined empirically was used to establish the
accuracy of the ELISA. The percent error between the
assigned value and the assay-determined value was 6.5%, as
determined from independent analyses by three individual
operators. These data are indicative of an acceptable level of
accuracy for this type of assay (9). The performance character-
istics of the AVR414 standard curve and of three positive qual-
ity control sera selected from humans vaccinated with AVA
were used to determine the precision (repeatability) of the anti-
PA ELISA. The positive quality control sera were tested in
duplicate at single dilutions selected to represent high,
medium, and low OD regions of the reference serum standard
curve. The percent error was 15.6% for quality control serum
#1 (n=55 tests), 20.2% for quality control serum #2 (n=92
tests), and 12.5% for quality control serum #3 (n=93 tests); the
Figure. Graphic representation of minimum detectable concentration
(MDC), reliable detection limit (RDL), and reactivity threshold. The MDC
is the concentration of anti-protective antigen antibody (anti-PA) corre-
sponding to the interpolated intersection of the lower asymptote of the
upper 95% confidence limit with the 4-parameter logistic log fit of the
standard curve data. The RDL is the concentration of anti-PA antibody
corresponding to the interpolated intersection of the lower asymptote of
the upper 95% confidence limit with the lower 95% confidence limit of
the standard’s data. The reactivity threshold was determined as the
upper 95% confidence limit of the frequency distribution from log10-
transformed optical density (OD) values of control human sera tested at
1/50 dilution. This OD value was converted to an anti-PA immunoglobu-
lin (Ig) G concentration by using the standard curve calibration factor.
Where this calculated value is below the MDC of the assay, the MDC
was selected as the default reactivity threshold.Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1107
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average percent error from the three sera was 16.2%. The pre-
cision within a single assay plate, as expressed by the intraas-
say coefficient of variation of the AVR414 standard curve, was
8.5%, and the interassay precision was 17.0%. These values
are within the accepted values of 10% and 20% for intraassay
and interassay precision, respectively (11), and are indicative
of a high level of precision for this type of assay (9). The
goodness of fit (mean R2) for the AVR414 standard curve cal-
culated over 54 runs was 0.99. On the basis of the determina-
tions of accuracy and precision given above, the range of
calculable concentrations from the AVA414 standard curve is
0.06–1.7 µg/mL of anti-PA IgG with an MDC and an RDL of
0.06 µg/mL and 0.09 µg/mL, respectively (n=54).
Limits of Quantification and Reactivity Threshold 
The limits of quantification are the lowest and highest con-
centrations of analyte that can be measured with a fixed degree
of precision. The fixed degree of precision for this assay has
been selected as a coefficient of variation (%CV) of 20% for
the calibrated antibody concentration of the reference standard
curve. For the anti-PA ELISA, the %CV for the calibrated anti-
body concentration is 20% for all of the standards data, indicat-
ing that the full extent of the AVR414 standard curve
encompassing the MDC and RDL can be used in calculating an
anti-PA IgG concentration for unknown sera and determining
the reactivity threshold. The reactivity threshold for this assay
was determined from the frequency distribution of log10-trans-
formed OD values from non-anthrax-related human control
sera. The geometric means for the OD values from 277 sera
from humans with non-anthrax-related clinical infections (544
observations) and 238 (476 observations) human control sera
were 0.059 (95% CI 0.018 to 0.253) and 0.050 (95% CI 0.021
to 0.138), respectively. The higher upper confidence limit of
0.253 was used for calculation of reactivity threshold. This cor-
responds to an anti-PA IgG concentration of 0.056 µg/mL, indi-
cating that the lower asymptote of the standard curve is within
the 95% CI of the control sera tested at the lowest dilution (1/
50) used in this assay (Figure). Because the upper confidence
limit of the control sera is less than the MDC (0.06 µg/mL) of
the assay, the MDC of a 1/50 diluted serum becomes the default
reactivity threshold and corresponds to an anti-PA IgG concen-
tration of 3.0 µg/mL in an undiluted serum sample. By the
same logic, a more conservative determination of reactivity
threshold could be derived from the RDL (0.09 µg/mL) corre-
sponding to a concentration of 4.5 µg/mL in an undiluted
serum sample. However, using the MDC to derive the reactiv-
ity threshold maximizes the sensitivity of the assay without
compromising specificity; thus, the reactivity threshold of 3.0
µg/mL was selected as the lower limit of quantification.
DSN and DSP
The reactivity threshold was used to categorize sera as
reactive or nonreactive and then to determine the DSN and
DSP of the assay. The reactivity threshold was determined
empirically, avoiding assumptions on the antibody response
rate following exposure to anthrax toxin PA whether by vacci-
nation or clinical infection. The lack of counts in the false-pos-
itive cells (Table) for vaccinee and clinical anthrax sera and
the lack of counts in the false-negative cells for normal and
non-anthrax infection sera can be qualified on both their
known exposure to PA and their reactivity in the anti-PA IgG
ELISA. Because only a few serum specimens from clinically
positive anthrax cases were available at the start of this emer-
gency response, the DSN of the anti-PA IgG ELISA was ini-
tially determined by using 68 sera from a cohort of sera
donated by AVA vaccinees. For this sample cohort, the num-
bers of true positives and false negatives were 67 and 1,
respectively. The DSN of the assay under these conditions is
therefore 98.5% (Table). When the control sera from the same
sample set of donors were used, the numbers of true negatives
and false positives were 15 and 4, respectively, suggesting a
diagnostic specificity of 78.9% for determining whether
Table. Calculation of diagnostic sensitivity and diagnostic specificity by using cohorts of known vaccination or infection statusa
Serum test group AVA vaccinees Non-Vaccinees
NHANES 
controls
Non-anthrax 
infections
Clinical 
anthrax serab
Total sera of known infection 
and vaccination status
True positivesc 67 0 0 0 15 82
True negativesd 0 15 228 260 0 503
False positivese 0 4 10 17 0 31
False negativesf 1000 1 2
Total 68 19 238 277 16 618
Diagnostic specificity n/a 78.9% 95.7% 93.8% n/a 94.2%
Diagnostic sensitivity 98.5% n/a n/a n/a 93.7% 97.6%
aAVA, anthrax vaccine adsorbed; NHANES, National Health and Nutrition Examination Survey; n/a, not applicable.
bClinical anthrax sera were obtained from donors that met the Centers for Disease Control and Prevention case definition for confirmed cutaneous and inhalational anthrax. Patients 
were classified as either reactive or nonreactive.
cSera are considered true positives if they were obtained from clinically confirmed anthrax cases or from donors with a documented history of anthrax vaccination.
dTrue-negative sera were selected on the basis of having no known exposure to Bacillus anthracis infection and no known anthrax vaccination.
eFalse-positive sera are defined as sera which reacted (>3.0 µg/mL) in the anti-protective antigen immunoglobulin G enzyme-linked immunosorbent assay but for which there is no 
history of clinical anthrax or anthrax vaccination.
fFalse-negative sera are defined as sera from donors who are documented as vaccine recipients or had clinically confirmed anthrax.BIOTERRORISM-RELATED ANTHRAX
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ELISA reactivity is due to an exposure to anthrax toxin PA
(Table).
However, separate analyses of two further serum cohorts
(sera from clinical infections other than anthrax and sera from
NHANES negative controls) returned DSP values of 93.8%
and 95.7%, respectively (Table). Combined analysis of all sera
of known infection or known vaccination status, including sera
from the 21 confirmed clinical anthrax cases, indicated an
overall DSN of 97.8% and consequently a 2.2% frequency of
potential false positives (Table).
Discussion
The focus of this report is to describe the qualification and
performance characteristics of an ELISA for anti-PA IgG anti-
bodies and enhancement of its specificity by using a second-
stage CI-ELISA. The application of these assays to the analy-
sis of the antibody response following anthrax infection
(Quinn CP et al., manuscript in preparation) and for serologic
surveillance from clinical anthrax cases will be reported in
detail elsewhere (13,14). Historically, if not identified and
treated early, systemic anthrax in humans was invariably fatal.
As a consequence, serologic assays have not featured promi-
nently in the diagnosis of clinical anthrax and in some reports
have been considered unreliable for early identification of the
disease or for establishing a retrospective diagnosis (15). Sero-
logic assays for anthrax have primarily been applied for the
evaluation of immune responses to anthrax vaccines, in epide-
miologic investigations of the disease in animals, and in con-
firmatory diagnosis of the various manifestations of anthrax in
humans (16–18). A useful adjunct to serologic analysis of
anthrax infection is the Anthraxin test (19), which elicits a
localized delayed-type hypersensitivity reaction to intradermal
injection of a complex uncharacterized extract from attenuated
vegetative B. anthracis cells or edema fluid from B. anthracis–
infected animals. Anthraxin has been reported to be very accu-
rate for retrospective verification of anthrax in humans (20), to
be applicable for up to 30 years after infection (15), and to
have a qualitative positive correlation with anti-PA antibodies
in the sera from human clinical anthrax cases as detected by
ELISA (21). Anthraxin is not, however, approved by FDA as a
diagnostic reagent in the United States.
For nearly 4 decades, anthrax serologic studies depended
on the Ouchterlony agar gel diffusion test (16), which in turn
replaced complement fixation tests and in vivo passive protec-
tion and neutralization tests (22). The development of an indi-
rect (passive) microhemagglutination test (23) was the next
major progression in anthrax serologic testing. Based on the
agglutination by serum antibodies of sheep erythrocytes sensi-
tized with partially purified culture supernatants containing
anthrax toxin PA (Factor II) (24), this test provided greater
sensitivity and speed than the agar gel diffusion technique. The
microhemagglutination assay, however, was laborious to set
up because antigen-coated erythrocytes had only a short shelf
life, and variation in erythrocyte batches compromised repro-
ducibility (25). 
The microhemagglutination assay was replaced by the
more sensitive and reproducible ELISA system, which has
been applied in various formats including the immobilized
antigen (direct) assay (25), an immobilized anti-PA antibody
(antigen-capture) assay (26), and a competition ELISA (27),
with, where reported, varying degrees of specificity and sensi-
tivity (17,18,28). Turnbull et al. (29) described using ELISA to
confirm anthrax in humans and demonstrated that recipients of
the licensed AVA could be distinguished from persons with
natural infections on the basis of their lack of reactivity to the
anthrax toxin lethal factor protein. Sirisanthana et al. (17) in a
serologic study of anthrax in northern Thailand and Harrison
et al. (18) in a serologic study of anthrax in Paraguay
described use of both ELISA and Western blot to retrospec-
tively evaluate seroconversion in cutaneous and oral-oropha-
ryngeal anthrax. In both studies, separate ELISAs were
applied for the detection of anti-toxin and anti-capsule anti-
body responses, and Western blot was used to enhance the
specificity of serologic diagnosis (17,18). Turnbull et al. (16)
reported the detection of anti-PA antibodies in humans and
animals in the Etosha National Park and also concluded that
there is a residual antibody level in these populations in an
area where the disease is endemic. However, the specificity
and sensitivity of the ELISA used in that study were not
reported, and the frequency of anti-PA antibodies in bacterio-
logically confirmed clinical cases was a maximum of 71%
(16). The prevalence of true positive anti-PA antibody reactiv-
ity in the general human population therefore remains
unknown, although our study of 515 non-anthrax-related con-
trol sera suggests that it is probably <7%.
The anti-PA ELISA developed and qualified at CDC
before being applied in the anthrax emergency has a MDC of
0.06 µg/mL, an RDL of 0.09 µg/mL, and a reactivity threshold
of 3.0 µg/mL anti-PA IgG. The reactivity threshold was
adopted as the lower limit of quantification. The DSN of the
assay is 97.6%, and the DSP is 94.2%. The CI-ELISA
enhanced DSP to 100%. These results represent substantial
improvements over the published sensitivities for anti-PA ELI-
SAs of 72% (17) and 91.7% (18). Although Harrison et al.
(18) reported a specificity of 100%, this was on a sample size
of 18 controls, compared with the sample size reported here of
515 control sera (277 non-anthrax-related sera plus 238
NHANES controls). An additional important outcome of this
study is the provision of a standard reference serum that can be
used in a variety of serologic assays for the detection and
quantification of anti-PA antibodies.
When evaluating the importance of a reactive serologic
result, the prevalence of disease in the group of interest should
first be considered. The assays reported in this study were pri-
marily applied as a part of a panel of laboratory tests for the
confirmation of clinical human anthrax in patients in whom
the disease prevalence is expected to be high (30). The assays
were also applied to serologic surveys of patients who may
have been exposed to spores of B. anthracis, a group in which
the disease prevalence may be expected to be low (13,14). ForEmerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1109
BIOTERRORISM-RELATED ANTHRAX
assays in which the specificity and sensitivity have been deter-
mined to be high (>90%), a reactive serum in a low-prevalence
group has a much greater probability of being a false positive
than it does in a high-prevalence group (31). Conversely, in the
high-prevalence group nonreactive sera may not be indicative
of the absence of disease. In practice, the 2.2% frequency of
potential false positives reported here rarely presented a prob-
lem, and seroconversion was detectable by a >4-fold rise in
anti-PA IgG concentration above the assay reactivity threshold
or the acute-phase serum in all but three patients (data not
shown), where paired samples with an appropriate time inter-
val between them were available (0–7 days after symptoms for
acute-phase sera and 14–28 days after symptoms for convales-
cent-phase sera). 
The necessity for a rapid public health response meant that
optimizing the number and timing of the patient serum collec-
tion was not always feasible or practicable. As a result, there
was a high frequency of single (i.e., unpaired) sera from cases
under investigation. To provide adequate analysis of these sin-
gle sera and also for paired sera that were reactive but did not
demonstrate changing levels of reactivity with time, a compet-
itive rPA inhibition ELISA (CI-ELISA) was developed based
on the qualified anti-PA ELISA. The objective of the CI-
ELISA was to increase the DSP of the ELISA by reducing the
incidence of false positives. The CI-ELISA effectively demon-
strated the specificity of the ELISA format by using sera from
AVA vaccinees and clinically confirmed anthrax cases (8).
Although very little published information supports the
suggestion that antibiotic therapy can suppress the humoral
immune response (32), anthrax infection studies in nonhuman
primates have shown that early antibiotic treatment after a
known challenge with B. anthracis spores abrogates an anti-
PA antibody response (33). A plausible explanation for this is
that early intervention in the infection process minimizes anti-
gen presentation to the immune system. The implication, par-
ticularly for cutaneous anthrax in the context of a response to a
bioterrorist attack, when antibiotic intervention is likely to be
rapid and aggressive (2), is that serologic tests should not be
used as the sole confirmatory tests for anthrax. 
Conclusion
In this bioterrorism-related anthrax outbreak, the rapid
adaptation and laboratory qualification of a quantitative sero-
logic assay for IgG antibodies to the PA component of anthrax
toxin contributed to the emergency public health response. The
qualified ELISA is accurate, sensitive, specific, reproducible,
and quantitative, providing fractional concentrations of anti-
PA IgG antibodies. This assay, together with the supplemental
CI-ELISA, proved to be an invaluable tool for assisting in
early diagnosis of cutaneous and inhalational anthrax cases. 
Timing of the sample and specimen quality are critical ele-
ments in successful confirmation of anthrax, particularly cuta-
neous anthrax, where antibiotic therapy has been implemented
and the onset of antibody production may be later and of lower
magnitude than for inhalational anthrax. To provide an accu-
rate clinical picture on which to base diagnosis and thus treat-
ment, serologic testing is most appropriately used as one of a
series of laboratory tests, together with a known exposure or
clinical presentation consistent with anthrax.
Ongoing studies on the ability of reactive serum from clin-
ical cases to neutralize anthrax toxin in vitro in a macrophage
cytotoxicity assay may help to better describe the complex pic-
ture of immune responses to anthrax and determine whether
the detection of a serologic response to anthrax toxin PA in
humans infected during the bioterrorist attack of fall 2001
indicates protection against further exposure to this disease.
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